Systematic reviews and meta-analyses are valuable tools for understanding existing-and shaping future-medical research. The concepts of systematic reviews and meta-analysis were introduced more than 40 years ago and adopted into mainstream medical research shortly thereafter. When well performed, including the choice of a relevant topic, systematic reviews and meta-analyses can provide useful insights into disease diagnosis, epidemiology, treatment effects (including benefits and harms), and aspects of study design or populations that might be associated with (and possibly influence) treatment effectiveness or other outcomes, including adverse events. These effects may become apparent in a meta-analysis when not readily evident from individual small studies. Nearly half a century later, these objectives remain central, although additional applications and more rigorous methods have been developed. wever, as noted in a commentary by Berlin et al, 4 there is great variability in the quality of published meta-analyses, particularly with regard to whether they were conducted in a transparent, reproducible, and valid manner. In this vein, there are numerous existing guidance documents relating to the conduct or reporting of systematic reviews and meta-analyses, eg, the Cochrane Handbook and Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. other issue is the massive increase in meta-analyses and systematic reviews published during the past 3 decades, many of which are likely redundant or misleading. This trend presents a challenge for the editors of JAMA Network Open in terms of the volume of systematic reviews and meta-analyses, including network meta-analyses, that are routinely submitted. In 2021, there were 655 meta-analyses and 175 systematic reviews submitted, with 56 (9%) and 29 (17%) accepted, respectively. Although we have not established explicit standards for determining whether a submitted systematic review or meta-analysis should be accepted, the editors of JAMA Network Open have implicitly developed criteria by which to judge these submissions. The issues extend beyond methodological rigor, which is a fundamental requirement, to include the crucial questions of what makes the meta-analysis important and interesting. To clarify our expectations, and in the process, improve the chance that a manuscript might be considered further, we ask that authors of meta-analyses and systematic reviews to address a series of key questions in their cover letter:
No takes yet. Share an insight, caveat, or question.
Berlin et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: